Symbols / NUWE
NUWE Chart
About
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Indonesia, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 1.52M |
| Enterprise Value | -34.33K | Income | -16.56M | Sales | 8.17M |
| Book/sh | 2.86 | Cash/sh | 1.86 | Dividend Yield | — |
| Payout | 0.00% | Employees | 38 | IPO | — |
| P/E | — | Forward P/E | -0.65 | PEG | — |
| P/S | 0.19 | P/B | 0.59 | P/C | — |
| EV/EBITDA | 0.00 | EV/Sales | -0.00 | Quick Ratio | 1.20 |
| Current Ratio | 2.04 | Debt/Eq | 9.79 | LT Debt/Eq | — |
| EPS (ttm) | -250.62 | EPS next Y | -2.59 | EPS Growth | -99.20% |
| Revenue Growth | -6.30% | Earnings | 2026-03-10 | ROA | -92.61% |
| ROE | -4.67% | ROIC | — | Gross Margin | 60.91% |
| Oper. Margin | -121.65% | Profit Margin | -202.83% | Shs Outstand | 902.66K |
| Shs Float | 1.64M | Short Float | 42.34% | Short Ratio | 0.06 |
| Short Interest | — | 52W High | 56.28 | 52W Low | 1.60 |
| Beta | -0.11 | Avg Volume | 2.17M | Volume | 44.62K |
| Target Price | — | Recom | None | Prev Close | $1.61 |
| Price | $1.68 | Change | 4.35% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$1.68
Latest analyst target
3. DCF / Fair value
$-254.99
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.68
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-08-13 | reit | Roth MKM | Buy → Buy | $17 |
| 2024-07-29 | init | Roth MKM | — → Buy | $17 |
| 2023-11-08 | down | Ladenburg Thalmann | Buy → Neutral | — |
- Three directors out, two new voices in at medical technology company Nuwellis - Stock Titan Fri, 23 Jan 2026 08
- Price-Driven Insight from (NUWE) for Rule-Based Strategy - Stock Traders Daily Sat, 21 Feb 2026 10
- NUWE Stock: How This $2 Microcap Secured An Infant Healthcare Monopoly - Nuwellis (NASDAQ:NUWE) - Benzinga ue, 27 Jan 2026 08
- Here’s Why Nuwellis Stock (NUWE) Rocketed Today - TipRanks ue, 27 Jan 2026 08
- Is Nuwellis Stock Built to Withstand More Downside? - Trefis Wed, 24 Dec 2025 08
- Nuwellis, Inc. to Announce Third Quarter 2025 Financial Results on November 12, 2025 - Quiver Quantitative hu, 23 Oct 2025 07
- Nuwellis stock falls after CFO appointment announcement - Investing.com Fri, 30 Jan 2026 08
- Nuwellis, Inc. (NUWE) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance ue, 13 May 2025 07
- Nuwellis (NUWE) Announces Stock Offering, Shares Plummet - GuruFocus Mon, 09 Jun 2025 07
- Nuwellis raises $5M by cutting warrant price in private deal - Stock Titan hu, 29 Jan 2026 08
- Morning Market Movers: NUWE, PHGE, BNAI, BZAI See Big Swings - RTTNews ue, 27 Jan 2026 08
- Nuwellis, Inc. Announces Private Placement of Common Stock and Warrant Inducement Agreement Expected to Raise $5 Million - Quiver Quantitative hu, 29 Jan 2026 08
- Nuwellis refreshes board amid linked capital raise plans - TipRanks Fri, 23 Jan 2026 08
- Nuwellis announces pricing of $4.3M underwritten public offering - Yahoo Finance ue, 10 Jun 2025 07
- Nuwellis stock falls after company terminates REVERSE-HF clinical trial - Investing.com hu, 17 Jul 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1100022 | 66001 | — | Conversion of Exercise of derivative security at price 0.06 per share. | ERB JOHN L | Chief Executive Officer | — | 2025-06-10 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 1.16M | 159.18K | 2.48M | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -10.76M | -17.11M | -16.72M | -19.06M |
| TotalUnusualItems | 5.51M | 758.00K | 11.83M | |
| TotalUnusualItemsExcludingGoodwill | 5.51M | 758.00K | 11.83M | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -11.16M | -20.21M | -14.53M | -19.55M |
| ReconciledDepreciation | 310.00K | 362.00K | 372.00K | 488.00K |
| ReconciledCostOfRevenue | 3.06M | 3.88M | 3.79M | 3.43M |
| EBITDA | -5.24M | -16.36M | -4.90M | -19.06M |
| EBIT | -5.55M | -16.72M | -5.27M | -19.55M |
| NetInterestIncome | -5.61M | -3.48M | -9.25M | 0.00 |
| InterestExpense | 5.61M | 3.48M | 9.25M | 0.00 |
| NormalizedIncome | -15.52M | -20.81M | -23.87M | -19.55M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -11.16M | -20.21M | -14.53M | -19.55M |
| TotalExpenses | 19.73M | 26.49M | 25.71M | 27.45M |
| TotalOperatingIncomeAsReported | -10.99M | -17.63M | -17.17M | -19.53M |
| DilutedAverageShares | 31.60K | 1.34K | 364.00 | 71.00 |
| BasicAverageShares | 31.60K | 1.34K | 364.00 | 71.00 |
| DilutedEPS | -353.22 | -16.93K | -947.80 | -6.50K |
| BasicEPS | -353.22 | -16.93K | -947.80 | -6.50K |
| DilutedNIAvailtoComStockholders | -10.62M | -22.63M | -14.53M | -19.63M |
| NetIncomeCommonStockholders | -10.62M | -22.63M | -14.53M | -19.63M |
| PreferredStockDividends | -541.00K | 2.42M | 75.00K | |
| NetIncome | -11.16M | -20.21M | -14.53M | -19.55M |
| NetIncomeIncludingNoncontrollingInterests | -11.16M | -20.21M | -14.53M | -19.55M |
| NetIncomeContinuousOperations | -11.16M | -20.21M | -14.53M | -19.55M |
| TaxProvision | 5.00K | 8.00K | 9.00K | 9.00K |
| PretaxIncome | -11.16M | -20.20M | -14.52M | -19.55M |
| OtherIncomeExpense | 5.43M | 912.00K | 11.90M | -19.00K |
| OtherNonOperatingIncomeExpenses | -80.00K | 154.00K | 75.00K | -19.00K |
| SpecialIncomeCharges | 900.00K | 0.00 | ||
| OtherSpecialCharges | -900.00K | |||
| GainOnSaleOfSecurity | 4.62M | 758.00K | 11.83M | |
| NetNonOperatingInterestIncomeExpense | -5.61M | -3.48M | -9.25M | 0.00 |
| InterestExpenseNonOperating | 5.61M | 3.48M | 9.25M | 0.00 |
| OperatingIncome | -10.99M | -17.63M | -17.17M | -19.53M |
| OperatingExpense | 16.66M | 22.61M | 21.93M | 24.02M |
| ResearchAndDevelopment | 3.21M | 5.42M | 4.34M | 4.98M |
| SellingGeneralAndAdministration | 13.46M | 17.19M | 17.58M | 19.04M |
| GrossProfit | 5.68M | 4.98M | 4.75M | 4.49M |
| CostOfRevenue | 3.06M | 3.88M | 3.79M | 3.43M |
| TotalRevenue | 8.74M | 8.86M | 8.54M | 7.92M |
| OperatingRevenue | 8.74M | 8.86M | 8.54M | 7.92M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 104.14K | 3.87K | 364.00 | 71.00 |
| ShareIssued | 104.14K | 3.87K | 364.00 | 71.00 |
| TotalDebt | 545.00K | 760.00K | 984.00K | 1.18M |
| TangibleBookValue | 6.53M | 2.99M | 12.36M | 25.95M |
| InvestedCapital | 6.53M | 2.99M | 12.36M | 25.95M |
| WorkingCapital | 6.30M | 5.04M | 18.08M | 24.82M |
| NetTangibleAssets | 6.53M | 3.21M | 12.36M | 25.95M |
| CapitalLeaseObligations | 545.00K | 760.00K | 984.00K | 1.18M |
| CommonStockEquity | 6.53M | 2.99M | 12.36M | 25.95M |
| PreferredStockEquity | 2.00K | 221.00K | ||
| TotalCapitalization | 6.53M | 3.21M | 12.36M | 25.95M |
| TotalEquityGrossMinorityInterest | 6.53M | 3.21M | 12.36M | 25.95M |
| StockholdersEquity | 6.53M | 3.21M | 12.36M | 25.95M |
| GainsLossesNotAffectingRetainedEarnings | -47.00K | -31.00K | 38.00K | -35.00K |
| OtherEquityAdjustments | 56.00K | -24.00K | ||
| ForeignCurrencyTranslationAdjustments | -47.00K | -31.00K | -18.00K | -11.00K |
| UnrealizedGainLoss | 56.00K | -24.00K | ||
| RetainedEarnings | -298.79M | -287.63M | -267.42M | -252.89M |
| AdditionalPaidInCapital | 305.37M | 290.65M | 279.74M | 278.87M |
| CapitalStock | 2.00K | 221.00K | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| PreferredStock | 2.00K | 221.00K | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 3.33M | 6.56M | 12.32M | 4.47M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 775.00K | 3.39M | 7.63M | 1.16M |
| OtherNonCurrentLiabilities | 179.00K | |||
| DerivativeProductLiabilities | 468.00K | 2.84M | 6.87M | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 307.00K | 544.00K | 760.00K | 984.00K |
| LongTermCapitalLeaseObligation | 307.00K | 544.00K | 760.00K | 984.00K |
| CurrentLiabilities | 2.56M | 3.17M | 4.69M | 3.31M |
| OtherCurrentLiabilities | 41.00K | 51.00K | 58.00K | 36.00K |
| CurrentDebtAndCapitalLeaseObligation | 238.00K | 216.00K | 224.00K | 193.00K |
| CurrentCapitalLeaseObligation | 238.00K | 216.00K | 224.00K | 193.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 640.00K | 525.00K | 2.16M | 1.66M |
| PayablesAndAccruedExpenses | 1.64M | 2.38M | 2.25M | 1.41M |
| Payables | 1.64M | 2.38M | 2.25M | 1.41M |
| AccountsPayable | 1.64M | 2.38M | 2.25M | 1.41M |
| TotalAssets | 9.86M | 9.77M | 24.67M | 30.42M |
| TotalNonCurrentAssets | 1.01M | 1.56M | 1.90M | 2.29M |
| OtherNonCurrentAssets | 21.00K | 120.00K | 21.00K | 21.00K |
| NetPPE | 988.00K | 1.44M | 1.88M | 2.27M |
| AccumulatedDepreciation | -3.78M | -3.48M | -3.17M | -2.82M |
| GrossPPE | 4.77M | 4.92M | 5.05M | 5.09M |
| Leases | 253.00K | 253.00K | 253.00K | 245.00K |
| OtherProperties | 3.45M | 3.61M | 3.71M | 3.77M |
| MachineryFurnitureEquipment | 1.07M | 1.06M | 1.09M | 1.08M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 8.86M | 8.21M | 22.77M | 28.13M |
| OtherCurrentAssets | 315.00K | 461.00K | 396.00K | 328.00K |
| Inventory | 1.72M | 2.00M | 2.66M | 2.84M |
| InventoriesAdjustmentsAllowances | -235.00K | -75.00K | -145.00K | -241.00K |
| FinishedGoods | 512.00K | 393.00K | 993.00K | 1.53M |
| WorkInProcess | 131.00K | 207.00K | 204.00K | 276.00K |
| RawMaterials | 1.31M | 1.47M | 1.61M | 1.28M |
| Receivables | 1.73M | 1.95M | 1.41M | 750.00K |
| AccountsReceivable | 1.73M | 1.95M | 1.41M | 750.00K |
| CashCashEquivalentsAndShortTermInvestments | 5.09M | 3.80M | 18.31M | 24.20M |
| OtherShortTermInvestments | 0.00 | 569.00K | 15.46M | |
| CashAndCashEquivalents | 5.09M | 3.80M | 17.74M | 8.74M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -9.65M | -18.18M | -15.27M | -18.06M |
| RepaymentOfDebt | 0.00 | -28.00K | -26.00K | -26.00K |
| IssuanceOfCapitalStock | 8.43M | 3.59M | 9.45M | 27.90M |
| CapitalExpenditure | -60.00K | -248.00K | -122.00K | -219.00K |
| IncomeTaxPaidSupplementalData | 7.00K | 12.00K | 9.00K | 11.00K |
| EndCashPosition | 5.09M | 3.80M | 17.74M | 8.74M |
| BeginningCashPosition | 3.80M | 17.74M | 8.74M | 14.44M |
| EffectOfExchangeRateChanges | -16.00K | -13.00K | -7.00K | -4.00K |
| ChangesInCash | 1.31M | -13.92M | 9.00M | -5.69M |
| FinancingCashFlow | 10.96M | 3.68M | 9.42M | 27.87M |
| CashFlowFromContinuingFinancingActivities | 10.96M | 3.68M | 9.42M | 27.87M |
| ProceedsFromStockOptionExercised | 2.53M | 120.00K | 0.00 | 1.00K |
| NetPreferredStockIssuance | 501.00K | 1.48M | 0.00 | |
| PreferredStockIssuance | 501.00K | 1.48M | 0.00 | |
| NetCommonStockIssuance | 7.93M | 2.11M | 9.45M | 27.90M |
| CommonStockIssuance | 7.93M | 2.11M | 9.45M | 27.90M |
| NetIssuancePaymentsOfDebt | 0.00 | -28.00K | -26.00K | -26.00K |
| NetLongTermDebtIssuance | 0.00 | -28.00K | -26.00K | -26.00K |
| LongTermDebtPayments | 0.00 | -28.00K | -26.00K | -26.00K |
| InvestingCashFlow | -60.00K | 330.00K | 14.73M | -15.72M |
| CashFlowFromContinuingInvestingActivities | -60.00K | 330.00K | 14.73M | -15.72M |
| NetInvestmentPurchaseAndSale | 0.00 | 578.00K | 14.85M | -15.50M |
| SaleOfInvestment | 0.00 | 578.00K | 14.85M | 3.35M |
| PurchaseOfInvestment | 0.00 | -18.85M | ||
| NetIntangiblesPurchaseAndSale | 0.00 | -99.00K | 0.00 | |
| PurchaseOfIntangibles | 0.00 | -99.00K | 0.00 | |
| NetPPEPurchaseAndSale | -60.00K | -149.00K | -122.00K | -219.00K |
| SaleOfPPE | 0.00 | |||
| PurchaseOfPPE | -60.00K | -149.00K | -122.00K | -219.00K |
| OperatingCashFlow | -9.59M | -17.94M | -15.15M | -17.84M |
| CashFlowFromContinuingOperatingActivities | -9.59M | -17.94M | -15.15M | -17.84M |
| ChangeInWorkingCapital | -305.00K | -1.42M | 598.00K | -104.00K |
| ChangeInOtherWorkingCapital | -22.00K | -7.00K | -96.00K | 186.00K |
| ChangeInOtherCurrentAssets | -160.00K | -65.00K | -68.00K | -91.00K |
| ChangeInPayablesAndAccruedExpense | -626.00K | -1.50M | 1.28M | -211.00K |
| ChangeInInventory | 279.00K | 697.00K | 140.00K | -143.00K |
| ChangeInReceivables | 224.00K | -545.00K | -656.00K | 155.00K |
| ChangesInAccountReceivables | 224.00K | -545.00K | -656.00K | 155.00K |
| OtherNonCashItems | 5.61M | 3.48M | 9.25M | |
| StockBasedCompensation | 478.00K | 670.00K | 862.00K | 1.31M |
| DepreciationAmortizationDepletion | 310.00K | 362.00K | 372.00K | 488.00K |
| DepreciationAndAmortization | 310.00K | 362.00K | 372.00K | 488.00K |
| OperatingGainsLosses | -4.52M | -823.00K | -11.70M | 13.00K |
| GainLossOnInvestmentSecurities | -4.62M | -823.00K | -11.70M | 13.00K |
| NetForeignCurrencyExchangeGainLoss | 0.00 | |||
| GainLossOnSaleOfPPE | 99.00K | 0.00 | 0.00 | |
| NetIncomeFromContinuingOperations | -11.16M | -20.21M | -14.53M | -19.55M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for NUWE
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|